Looking back on 2022, although the popularity of acquisitions in the pharmaceutical industry has decreased compared with the previous year, it is still remarkable
.
According to the 2022 pharmaceutical acquisitions compiled by Fengshuo Venture Capital, the top 10 pharmaceutical acquisition cases by acquisition amount mainly involved 7 multinational pharmaceutical companies
such as Amgen, Pfizer, BMS, and GSK.
Pharmaceutical industry (Image source: Pharmaceutical Network)
A number of multinational pharmaceutical companies have dealt more than US$2 billion
Among them, Amgen acquired Horizon for US$28.
3 billion, including the latter's thyroid eye disease product TEPEZZA, which set a new record
for the acquisition amount of pharmaceutical companies in the pharmaceutical and health field in 2022.
It was followed by Pfizer, which acquired Biohaven for a total of $11.
6 billion, giving access to the latter's potential calcitonin gene-associated peptide (CGRP) receptor antagonists, including NURTEC ODT, Zavegepant, and a portfolio
of preclinical CGRP assets.
Looking back at 2022, Pfizer's acquisitions are frequent, in addition to Biohaven, Pfizer has also acquired Arena, Global Blood Therapeutics, and ReViral
for $6.
7 billion, $5.
4 billion and $1 billion.
In addition, multinational pharmaceutical companies such as BMS, GSK, Sumitovant, and Samsung Biologics have also launched large-scale acquisitions in 2022, involving transactions of more than US$2 billion
.
Rare diseases and oncology tracks are highly favored
Judging from the track of the above-mentioned large-scale acquisitions of multinational pharmaceutical companies and the blockbuster products (including products under development), it is not difficult to find a phenomenon: multinational pharmaceutical companies are accelerating their layout in the field of
tumors and rare diseases through large-scale mergers and acquisitions 。 Whether it is Amgen's acquisition of Horizon, Pfizer's Global Blood Therapeutics, BMS's Turning Point, Sumitovant's Myovant, UCB's Zoegenix, and GSK's Sierra, these multinational pharmaceutical companies have basically acquired large amounts in the field of
rare diseases and tumors.
The analysis believes that this phenomenon reflects the optimism of multinational pharmaceutical companies on the market prospects of tumors and rare diseases, and the determination
of multinational pharmaceutical companies to lay out these two major tracks.
As far as the oncology industry is concerned, with the aging of the population and the change of living habits, the incidence
of tumor patients is high.
According to data published by the World Health Organization's International Agency for Research on Cancer, there were about 19.
29 million new cancer cases worldwide in 2020, of which about 4.
57 million were
in China.
Among them, in developed countries, including colorectal cancer, breast cancer, thyroid cancer, prostate cancer and other tumors are showing a continuous upward trend, in China, including lung cancer, liver cancer, breast cancer and other patients are also growing
.
These conditions are stimulating the growth of the global oncology drug market and the demand for oncology drug market in China
.
Data show that the global oncology drug market size is expected to increase from $181.
7 billion to $341.
1 billion from 2021 to 2026, and to $484.
5 billion by 2030, with compound annual growth rates of 13.
4% and 9.
2%
from 2021 to 2026 and 2026 to 2030, respectively 。 The size of China's oncology drug market is also expected to grow rapidly, from US$35.
8 billion in 2021 to US$69.
5 billion in 2026, with a compound annual growth rate of 14.
2%, and exceed US$100 billion in 2030 to reach US$101 billion, with a compound annual growth rate of 9.
8%.
However, at present, there is still a huge unmet clinical treatment demand for the majority of cancers, which still needs to be continuously developed and explored
by pharmaceutical companies.
In addition, in the rare disease track, according to the "2022 China Rare Disease Industry Trend Observation Report" released by Frost & Sullivan and Beijing Pain Challenge Public Welfare Foundation, there are more than 7,000 known rare diseases in the world, and the global rare disease patients have exceeded 300 million, of which there are about 20 million rare disease patients in China, but the demand for rare disease drugs in the vast patient population is still urgent
.
Frost & Sullivan predicts that the global rare disease drug market will increase from $135.
1 billion in 2020 to $383.
3 billion in 2030, with a compound annual growth rate of 11%.
Aiming at the blue ocean of two hundred billion US dollars market, compared with the high investment and high risk associated with self-research, the industry believes that multinational pharmaceutical companies can enrich their product pipelines more quickly through mergers and acquisitions, improve their competitiveness in the field of tumors and rare diseases, and further improve the growth points
of corporate performance.
It is worth mentioning that among the companies acquired by the above-mentioned multinational pharmaceutical companies in 2022, a total of 7 products are in the commercialization stage, significantly exceeding the 5 and 3 in 2021 and 2020
.
In this regard, the analysis believes that this may indicate that multinational pharmaceutical companies pay more attention to
whether they can improve their financial statements in the short term in terms of large-scale acquisitions.
In 2023, the pace of mergers and acquisitions of multinational pharmaceutical companies may accelerate
Looking forward to 2023, the industry believes that investment in the healthcare sector is expected to pick up, and it is expected that multinational pharmaceutical companies that have launched mergers and acquisitions in recent years may still return to accelerate the pace
of mergers and acquisitions.
Recently, for example, Goldman Sachs estimated that Pfizer still has more than $100 billion in additional capital available for M&A deals
in 2023, taking into account cash flow and debt capacity.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
